Important progress in the treatment of head and neck squamous cell carcinoma (HNSCC) has been made with the discovery of anti-EGFR and anti-PD-L1 therapy and their implementation into treatment protocols [9,10,11]. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.